KeyBanc upgrades Exagen stock to Overweight on improved pricing and growth

Published 30/07/2025, 08:04
KeyBanc upgrades Exagen stock to Overweight on improved pricing and growth

Investing.com - KeyBanc upgraded Exagen (NASDAQ:XGN) stock rating from Sector Weight to Overweight and established a price target of $12.00, citing improved visibility on revenue growth. The stock, which has surged over 320% in the past year according to InvestingPro data, is currently trading near its 52-week high of $8.80.

The upgrade follows several impressive quarters for Exagen, a leader in autoimmune diagnostics primarily focused on lupus testing. KeyBanc noted that Exagen’s revenue guidance implies growth of 17-25% in 2025. With current revenues of $56.7 million and an overall Financial Health score rated as "FAIR" by InvestingPro, the company maintains a healthy current ratio of 2.32, indicating strong short-term liquidity.

Under CEO John Abelli, who joined in 2022, Exagen has strategically shed non-core tests and refocused on its core AVISE CTD test. This refocusing has achieved a 36% average selling price increase from fiscal year 2023 to the second quarter of 2025, reaching $428 with a long-term target exceeding $650.

The diagnostic company expects to deliver positive adjusted EBITDA in the fourth quarter of 2025 and for the full fiscal year 2026, according to KeyBanc’s analysis.

Exagen is also working to expand its market position in connective tissue diagnosis with new biomarkers planned for early 2026, which KeyBanc believes will increase the competitive moat around its core test and expand its pipeline of future diagnostics.

In other recent news, Exagen Inc . announced its second-quarter 2025 earnings, revealing significant developments. The company reported a revenue of $17.2 million, surpassing forecasts and marking the highest quarterly revenue in its history. Despite this achievement, Exagen’s earnings per share (EPS) did not meet expectations, with a reported loss of $0.21 compared to the anticipated $0.15 loss. These recent developments highlight the company’s ability to generate substantial revenue growth, although challenges remain in achieving expected profitability. The revenue results have been viewed positively by the market, reflecting investor confidence in Exagen’s potential for future growth. Additionally, the company’s performance has caught the attention of analysts, who may consider these figures in their future assessments. Investors will likely keep an eye on how Exagen addresses its profitability challenges while maintaining revenue growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.